Harnessing the stem cell potential: the path to prevent mitochondrial disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Disruptive Synergy: Melding of Human Genetics and Clinical Assisted Reproduction.Cell reports. Medicine · 2020
   Review
2. Assessing the fitness consequences of mitonuclear interactions in natural populations.Biological reviews of the Cambridge Philosophical Society · 2019
   Article
3. Overcoming bioethical, legal, and hereditary barriers to mitochondrial replacement therapy in the USA.Journal of assisted reproduction and genetics · 2019
   Article
4. Mitonuclear linkage disequilibrium in human populations.Proceedings. Biological sciences · 2015
   Article
5. Risks inherent to mitochondrial replacement.EMBO reports · 2015
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as